WO2001013898A3 - Pharmaceutical formulations with different release times - Google Patents

Pharmaceutical formulations with different release times Download PDF

Info

Publication number
WO2001013898A3
WO2001013898A3 PCT/GB2000/003309 GB0003309W WO0113898A3 WO 2001013898 A3 WO2001013898 A3 WO 2001013898A3 GB 0003309 W GB0003309 W GB 0003309W WO 0113898 A3 WO0113898 A3 WO 0113898A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
dosage form
pharmaceutical formulations
delaying
delayed
Prior art date
Application number
PCT/GB2000/003309
Other languages
French (fr)
Other versions
WO2001013898A2 (en
Inventor
Christian Andina
Niall Fanning
Fiona Palmer
Paul Stark
Original Assignee
Elan Corp Plc
Christian Andina
Niall Fanning
Fiona Palmer
Paul Stark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc, Christian Andina, Niall Fanning, Fiona Palmer, Paul Stark filed Critical Elan Corp Plc
Priority to AU67156/00A priority Critical patent/AU6715600A/en
Priority to EP00954802A priority patent/EP1206250A2/en
Priority to CA002380333A priority patent/CA2380333A1/en
Priority to JP2001518036A priority patent/JP2003507416A/en
Publication of WO2001013898A2 publication Critical patent/WO2001013898A2/en
Publication of WO2001013898A3 publication Critical patent/WO2001013898A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

The application discloses novel pharmaceutical formulations adapted for delaying the release of a pharmaceutically active agent. A delayed-release drug formulation encapsulates the active ingredient, which may be applied to microparticles or in tableted form, in a release-delaying coat comprising polymeric materials of predetermined swelling/permeability characteristics. In particular, acrylate and/or acrylic acid polymer blends modified with ionic groups may be used. One preferred embodiment uses a polymer of pH dependent permeability as a more permeable element of the coat. The delayed-release formulations are deployed in a single dosage form together with instant release or sustained release formulations, so that a unit dosage form, preferably an oral dosage form, can effectively administer two doses to a patient at different times.
PCT/GB2000/003309 1999-08-26 2000-08-29 Pharmaceutical formulations with different release times WO2001013898A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU67156/00A AU6715600A (en) 1999-08-26 2000-08-29 Pharmaceutical formulations
EP00954802A EP1206250A2 (en) 1999-08-26 2000-08-29 Pharmaceutical formulations with different release times
CA002380333A CA2380333A1 (en) 1999-08-26 2000-08-29 Pharmaceutical formulations
JP2001518036A JP2003507416A (en) 1999-08-26 2000-08-29 Pharmaceutical preparations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15088099P 1999-08-26 1999-08-26
US15089199P 1999-08-26 1999-08-26
US60/150,880 1999-08-26
US60/150,891 1999-08-26
US15121199P 1999-08-27 1999-08-27
US60/151,211 1999-08-27

Publications (2)

Publication Number Publication Date
WO2001013898A2 WO2001013898A2 (en) 2001-03-01
WO2001013898A3 true WO2001013898A3 (en) 2001-05-25

Family

ID=27387049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003309 WO2001013898A2 (en) 1999-08-26 2000-08-29 Pharmaceutical formulations with different release times

Country Status (4)

Country Link
EP (1) EP1206250A2 (en)
AU (1) AU6715600A (en)
CA (1) CA2380333A1 (en)
WO (1) WO2001013898A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
AU2003296852A1 (en) * 2002-09-18 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003301762B2 (en) * 2002-10-25 2006-02-09 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ES2241478B1 (en) * 2004-02-13 2006-11-16 Lacer S.A. PHARMACEUTICAL PREPARATION FOR THE SUSTAINED RELEASE OF A PHARMACEUTICALLY ACTIVE PRINCIPLE.
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US8865197B2 (en) 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
TW200711823A (en) * 2005-09-30 2007-04-01 Primax Electronics Ltd Laminating device and laminating method for use in same
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
KR101990951B1 (en) 2015-04-27 2019-06-20 주식회사 네비팜 A sustained releasing Pharmaceutical Composition comprising Rivastigmine
CN114159391B (en) * 2021-12-10 2023-05-05 卓和药业集团股份有限公司 Cabalatine bitartrate dry suspension and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5470584A (en) * 1991-05-20 1995-11-28 Carderm Capital L.P. Diltiazem formulation
WO2000019985A2 (en) * 1998-10-01 2000-04-13 Novartis Ag New sustained release oral formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5470584A (en) * 1991-05-20 1995-11-28 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
WO2000019985A2 (en) * 1998-10-01 2000-04-13 Novartis Ag New sustained release oral formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems

Also Published As

Publication number Publication date
WO2001013898A2 (en) 2001-03-01
CA2380333A1 (en) 2001-03-01
EP1206250A2 (en) 2002-05-22
AU6715600A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
WO2001013898A3 (en) Pharmaceutical formulations with different release times
RU2485942C2 (en) Bupropion hydrobromide and therapeutic applications thereof
HUP9904174A2 (en) Pharmaceutical composition for transdermic delivery
NO975872D0 (en) Formulations for controlled release of poorly soluble drugs
YU71894A (en) NEW PHARMACEUTICALS PREPARATION WITH DIFFUSION-OSMOTIC CONTROL OF LIBERATION AND THE PROCEDURE
ATE78157T1 (en) SLOW-RELEASE PHARMACEUTICALS.
DK0957900T3 (en) Compositions and Methods for Topical Application of Therapeutic Agents
DK1183014T3 (en) Flavored controlled release oral pharmaceutical compositions
RU2007126652A (en) COMPOSITIONS AND METHODS FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
DE60124294D1 (en) PROINSULIN C-PEPTIDE CONTAINING MEDICINE PREPARATION WITH DELAYED ACTIVE INGREDIENT RELEASE
DE69521688D1 (en) PHARMACEUTICAL Brewing Preparations Containing Biodegradable Microcapsules For Controlled Release Of Active Ingredients
DE60020501D1 (en) Trimetazidine-containing matrix tablet for prolonged release of active ingredient after oral administration
NO20031409D0 (en) Ion strength independent long-release pharmaceutical preparations
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use
EA200601285A1 (en) NON-DIFFERENT SOLID COMPOSITION FOR ORAL APPLICATION WITH HIGH DOSE OF MEDICINES AVAILABLE IN WATER
US6129931A (en) Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
DE69311394D1 (en) Delayed drug delivery
JP2002520269A5 (en)
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
YU25297A (en) A controlled release formulation for poorly soluble basic drugs
RU2002120047A (en) MEDICINAL FORM WITH PREVENTING TUBERCULOSIS
NZ532449A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and Crohn's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000954802

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380333

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000954802

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000954802

Country of ref document: EP